|
|
Multiple Myeloma Update From the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting
CME Information
|
|
|
|
Multiple myeloma is the second most prevalent blood cancer with more than 20,000 new cases reported annually and recent statistics indicating increase incidence and earlier age of onset. For decades, there had been limited therapeutic advances for myeloma patients as the understanding of the disease slowly increased. More recently, there has been tremendous progress in the field of myeloma research, and scientific advances now offer an unprecedented opportunity to treat myeloma patients. As new data emerge from clinical trials designed to improve upon current response rates, prolong survival, and minimize toxicities, it will be important to determine how these strategies may change current treatment guidelines and algorithms. Putting emerging clinical data into the context of whether or not these new data will affect current standards of care allowing for expert analysis will assist physicians in making patient-tailored treatment decisions.
|
|
|
|
This activity has been designed to meet the educational needs of hematologists and oncologists involved in the management of patients with multiple myeloma. |
|
|
|
After completing this activity, the participant will be able to
- Outline the clinical advancements in the treatment of patients with newly diagnosed myeloma
- Utilize novel targeted therapies for treating patients with relapsed and refractory myeloma
- Differentiate patients who are and are not eligible for stem cell transplantation
- Review side effect profiles of new myeloma therapies
- Implement prevention strategies for treatment-related toxicities
|
|
|
|
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine, the Multiple Myeloma Research Foundation, and cancereducation.com. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
|
|
|
|
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
|
|
|
- Robert Z. Orlowski, MD, PhD
The University of Texas
MD Anderson Cancer Center
Houston, TX
- Donna E. Reece, MD
Princess Margaret Hospital
Toronto, ON, Canada
- Jesus F. San Miguel, MD, PhD
Hospital Universitario de Salamanca
Salamanca, Spain
|
|
|
|
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity
Name of Faculty or Presenter |
Reported Financial Relationship |
 | |
Robert Z. Orlowski, MD, PhD |
Consulting Fees: Abbott Laboratories, Array BioPharma, Bristol-Myers Squibb, Celgene, Genentech, Millennium, Onyx
Contracted Research: Celgene, Millennium, Onyx, Bristol-Myers Squibb |
| |
Donna E. Reece, MD |
Consulting Fees: Onyx, Celgene, Janssen
Contracted Research: Celgene, Janssen, Millennium, Bristol-Myers Squibb, Otsuka |
| |
Jesus F. San Miguel, MD, PhD |
Consulting Fees: Millennium, Celgene, Novartis, Janssen, Onyx |
| |
Anne Quinn Young, MPH |
No financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
|
| |
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity
Name of Planner or Manager |
Reported Financial Relationship |
| |
Rich Parrish (cancereducation.com) |
No financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
|
| |
Michelle DiMichele (cancereducation.com)
|
No financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
|
| |
Laura Excell, ND, NP, MS, MA, LPC, NCC (PIM) |
No financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
|
| |
Trace Hutchison, PharmD (PIM) |
No financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
|
| |
Samantha Mattiucci, PharmD (PIM) |
No financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
|
| |
Jan Schultz, RN, MSN, CCMEP (PIM) |
No financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
|
| |
|
|
|
|
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
|
|
|
|
There are no fees for participating and receiving CME credit for this activity. During the period June 4, 2013 through June 30, 2014, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation online. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.
|
|
|
|
Web
|
|
|
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
|
|
|
This webcast makes use of the following requirements for proper viewing
- A broadband Internet connection with at least DSL or LAN speed
- Windows (XP, Vista, or 7) or Apple Intel-based Macintosh operating system
- Internet browser equivalent to or higher than Internet Explorer v7.x, Mozilla Firefox v2.0, Apple Safari v3.0
- Adobe Flash Player version 10. Click here to download the latest Flash Player
- A monitor with minimum resolution 800 x 600 (1024 x 768 or higher recommended)
- 2.4 GHz Intel Pentium IV processor or equivalent
- 256 MB of RAM
|
|
Click to continue
|
|